What are the advantages and disadvantages of mosapride compared with domperidone for pro‑kinetic therapy?

Mosapride vs Domperidone for Prokinetic Therapy

Direct Recommendation

Mosapride is the preferred prokinetic agent over domperidone for functional dyspepsia, offering comparable efficacy with a significantly lower risk of cardiac adverse events and fewer central nervous system side effects. 1, 2

---

Advantages of Mosapride Over Domperidone

Superior Safety Profile

• Mosapride carries substantially lower cardiovascular risk compared to domperidone, which is critical given domperidone's association with severe ventricular arrhythmias and QTc prolongation 2
• Mosapride does not readily cross the blood-brain barrier, eliminating the risk of extrapyramidal side effects and central dopaminergic adverse events that occur with domperidone 3
• Mosapride demonstrated lower total adverse event rates compared to domperidone in head-to-head network meta-analysis 1

Mechanism and Efficacy

• Mosapride acts as a selective 5-HT4 receptor agonist, enhancing acetylcholine release throughout the gastrointestinal tract, including the lower intestine and rectum 4
• Both agents show comparable efficacy for functional dyspepsia symptom relief, with no statistically significant difference in therapeutic response rates 1, 5
• Mosapride provides additional benefit for constipation in diabetic patients, increasing bowel frequency and improving reflux symptoms beyond upper GI effects 4

Pregnancy Safety

• Mosapride exposure during the first trimester shows no increased risk of major congenital anomalies (relative risk 1.02,95% CI 0.24-4.26), with reassuring pregnancy outcome data 6
• Domperidone crosses the placenta in animal studies and requires caution in pregnancy, though human data remain limited 3

---

Disadvantages of Mosapride Compared to Domperidone

Regulatory and Availability Issues

• Mosapride availability is limited primarily to Asian markets and is not FDA-approved in the United States, restricting its use in Western countries 7
• Domperidone, while also not FDA-approved in the US, can be accessed through investigational protocols, providing a pathway for use when metoclopramide fails 8, 9

Efficacy Considerations

• Network meta-analysis shows mosapride ranks lower in efficacy compared to metoclopramide and cinitapride, though the difference versus domperidone is not statistically significant 1, 5
• The British Society of Gastroenterology rates evidence quality for mosapride as "low," indicating less robust clinical trial data compared to some alternatives 7

Clinical Experience

• Domperidone has longer-established use in clinical practice with more extensive real-world experience, particularly in Europe and Canada 3
• Mosapride has fewer large-scale, long-term safety studies in diverse populations compared to domperidone 7

---

Practical Clinical Algorithm

First-Line Approach

• Start with mosapride 5 mg three times daily before meals when available, given superior safety profile 1, 4
• Reserve domperidone 10 mg three times daily for patients in regions where mosapride is unavailable or when mosapride fails after 4 weeks 8, 9

Cardiac Risk Assessment

• Avoid domperidone entirely in patients with QTc prolongation, cardiac arrhythmia history, or concurrent use of CYP3A4 inhibitors (erythromycin, ketoconazole) due to multi-fold increase in drug exposure 3, 2
• Mosapride represents the safer choice in elderly patients or those with cardiovascular comorbidities 2

Special Populations

• Choose mosapride for pregnant women requiring prokinetic therapy based on reassuring first-trimester safety data 6
• Select mosapride for diabetic patients with concurrent constipation to address both upper and lower GI symptoms 4

---

Critical Caveats

• Both agents are considered second-line after metoclopramide in guideline hierarchies, though metoclopramide carries its own significant risks (tardive dyskinesia, extrapyramidal symptoms) limiting use beyond 12 weeks 7, 8
• Neither mosapride nor domperidone should be used in patients with suspected gastrointestinal obstruction, as both are prokinetic agents that stimulate gut motility 3
• The evidence quality for both agents remains modest (low to moderate), with the British Society of Gastroenterology assigning weak recommendations for prokinetics overall 7
• Drug interactions must be carefully evaluated with domperidone, as P-glycoprotein substrates and CYP3A4 inhibitors dramatically increase exposure and arrhythmia risk 3